AstraZeneca is developing new labelling for its combination asthma medication Symbicort that could boost its prospects against rival drug Seretide/Advair from GlaxoSmithKline, according to Datamonitor ...

AstraZeneca turned up the pressure in its head-to-head battle with GlaxoSmithKline in the asthma arena yesterday, after winning approval for a new dosing regimen for its combination product Symbicort.

WASHINGTON, Jan. 11 (UPI) -- The anticipated approval of a new dosing regimen for AstraZeneca's Symbicort in Europe could significantly alter the asthma drug market, analysts said Wednesday. The ...

The SMART (Symbicort Maintenance and Reliever Therapy) approach allows patients to increase the dose of Symbicort (a combination of an inhaled corticosteroid and long-acting bronchodilator) during ...

The SmartTouch for Symbicort is a monitoring device that is installed onto the patient's inhaler to track and improve medication adherence. The Food and Drug Administration (FDA) has granted Adherium ...

The pediatric approval was based on the results of the Phase 3 CHASE (ChildHood Asthma Safety and Efficacy) 3 trial. The Food and Drug Administration (FDA) has approved Symbicort (budesonide and ...

(RTTNews) - The U.S. Food and Drug Administration approved Mylan Pharmaceuticals, Inc.'s generic of Symbicort (budesonide and formoterol fumarate dihydrate) inhalation aerosol. It is the first FDA- ...

Viatris’ new drug-device is the first FDA-approved generic version of AstraZeneca’s Symbicort. Kindeva Drug Delivery, a contract development and manufacturing organization, and Viatris announced FDA ...